InNexus Biotechnology (InNexus Biotechnology) Additional Paid-In Capital : $21.75 Mil(As of Mar. 2011)

View and export this data going back to . Start your Free Trial

What is InNexus Biotechnology Additional Paid-In Capital?

InNexus Biotechnology's quarterly additional paid-in capital increased from Sep. 2010 ($25.36 Mil) to Dec. 2010 ($26.33 Mil) but then stayed the same from Dec. 2010 ($26.33 Mil) to Mar. 2011 ($21.75 Mil).

InNexus Biotechnology's annual additional paid-in capital declined from Jun. 2008 ($22.68 Mil) to Jun. 2009 ($20.13 Mil) but then increased from Jun. 2009 ($20.13 Mil) to Jun. 2010 ($24.80 Mil).

InNexus Biotechnology Additional Paid-In Capital Historical Data

The historical data trend for InNexus Biotechnology's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InNexus Biotechnology Additional Paid-In Capital Chart

InNexus Biotechnology Annual Data

Trend

Jun01

Jun02

Jun03

Jun04

Jun05

Jun06

Jun07

Jun08

Jun09

Jun10

Additional Paid-In Capital

Get a 7-Day Free Trial

7.23

16.39

22.68

20.13

24.80

InNexus Biotechnology Quarterly Data
	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11
Additional Paid-In Capital	Get a 7-Day Free Trial															24.47	24.80	25.36	26.33	21.75

InNexus Biotechnology Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

InNexus Biotechnology Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of InNexus Biotechnology's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

InNexus Biotechnology (InNexus Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InNexus Biotechnology Inc (GREY:IXSBF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 West Georgia Street, 1500 Royal Centre, Vancouver, BC, CAN, V6E 4N7

Website

http://www.ixsbio.com

InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.

InNexus Biotechnology (InNexus Biotechnology) Headlines

No Headlines